Abrdn Life Sciences Investors (NYSE:HQL – Get Free Report) major shareholder Saba Capital Management, L.P. acquired 81,738 shares of the stock in a transaction that occurred on Thursday, April 18th. The stock was purchased at an average price of $12.80 per share, for a total transaction of $1,046,246.40. Following the completion of the acquisition, the insider now owns 2,694,511 shares in the company, valued at approximately $34,489,740.80. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Abrdn Life Sciences Investors Stock Performance
NYSE HQL opened at $12.98 on Tuesday. The stock’s 50 day simple moving average is $13.57 and its 200-day simple moving average is $13.09. Abrdn Life Sciences Investors has a 1-year low of $11.34 and a 1-year high of $14.37.
Abrdn Life Sciences Investors Increases Dividend
The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Thursday, February 22nd were issued a $0.39 dividend. The ex-dividend date was Wednesday, February 21st. This represents a $1.56 dividend on an annualized basis and a yield of 12.02%. This is a positive change from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.30.
Institutional Investors Weigh In On Abrdn Life Sciences Investors
About Abrdn Life Sciences Investors
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.
Further Reading
- Five stocks we like better than Abrdn Life Sciences Investors
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- Are Penny Stocks a Good Fit for Your Portfolio?
- Merger or Not, Albertson’s Companies is a Good Buy
- What is a Secondary Public Offering? What Investors Need to Know
- 3 Cheap Stocks That Shouldn’t Be So
Receive News & Ratings for Abrdn Life Sciences Investors Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abrdn Life Sciences Investors and related companies with MarketBeat.com's FREE daily email newsletter.